Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Bezafibrate[1] Bezafibrate[1] D01366 [1] PPARA 💬[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[7] 20, 93, 94, 160, 296, 316, 324
2Bezafibrate (drug)[1] Bezafibrate[1] D01366 [1] PPARA 💬[10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 316
3Break in L-carnitine treatment[1] Levocarnitine[3] D02030 ,
D02176 ,
D04713 		--[1] 316
4Carnitine[1] Levocarnitine[3] D02030 ,
D02176 ,
D04713 		--[9] 5, 13, 58, 86, 96, 97, 265, 298, 316
5Glycerol[1] Glycerin[1] D00028 --[5] 6, 13, 79, 316, 317
6Glycerol/Saline[1] Glycerin[1] D00028 --[2] 316, 317
7Heparin[1] Heparin[1] D07510 [1] SERPINC1 💬[1] Complement and coagulation cascades 💬[12] 47, 60, 70, 79, 84, 107, 224, 226, 280, 299, 316, 317
8Hyperinsulinemic euglycemic clamp----[2] 316, 317
9Intralipid/Heparin[1] Heparin[1] D07510 [1] SERPINC1 💬[1] Complement and coagulation cascades 💬[2] 316, 317
10L-Carnitine[1] Levocarnitine[3] D02030 ,
D02176 ,
D04713 		--[7] 13, 86, 96, 97, 265, 298, 316